secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0001493152-22-017558
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte appoints Bas van der Baan as independent director; grants 250K options at $0.74
--------------------------------------------------------------------------------

- Effective June 17, 2022, Bastiaan van der Baan appointed to Board as independent director.
- van der Baan brings 20+ years biotech oncology/diagnostics experience to clinical-stage LB-100 development.
- Granted options for 250,000 shares at $0.74 (closing price on grant date), 5-year term.
- Options vest 50% immediately, then 12.5% quarterly over four quarters, subject to continued service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315222017558/0001493152-22-017558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315222017558/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-017558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer